These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38571326)

  • 1. The bright side of chemistry: Exploring synthetic peptide-based anticancer vaccines.
    D'Aniello A; Del Bene A; Mottola S; Mazzarella V; Cutolo R; Campagna E; Di Maro S; Messere A
    J Pept Sci; 2024 Aug; 30(8):e3596. PubMed ID: 38571326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
    Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
    Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.
    Dutoit V; Taub RN; Papadopoulos KP; Talbot S; Keohan ML; Brehm M; Gnjatic S; Harris PE; Bisikirska B; Guillaume P; Cerottini JC; Hesdorffer CS; Old LJ; Valmori D
    J Clin Invest; 2002 Dec; 110(12):1813-22. PubMed ID: 12488431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation peptide vaccines for advanced cancer.
    Yamada A; Sasada T; Noguchi M; Itoh K
    Cancer Sci; 2013 Jan; 104(1):15-21. PubMed ID: 23107418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1.
    Campos-Perez J; Rice J; Escors D; Collins M; Paterson A; Savelyeva N; Stevenson FK
    Int J Cancer; 2013 Sep; 133(6):1400-7. PubMed ID: 23494538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-Linked Peptide Nanoclusters for Delivery of Oncofetal Antigen as a Cancer Vaccine.
    Tsoras AN; Champion JA
    Bioconjug Chem; 2018 Mar; 29(3):776-785. PubMed ID: 29436221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen-specific vaccines for cancer treatment.
    Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Composite peptide-based vaccines for cancer immunotherapy (Review).
    Yang J; Zhang Q; Li K; Yin H; Zheng JN
    Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
    Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
    BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines.
    Sotirov S; Dimitrov I
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.
    Robson NC; McAlpine T; Knights AJ; Schnurr M; Shin A; Chen W; Maraskovsky E; Cebon J
    Blood; 2010 Jul; 116(2):218-25. PubMed ID: 20430956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
    Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
    Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells.
    Muraoka D; Kato T; Wang L; Maeda Y; Noguchi T; Harada N; Takeda K; Yagita H; Guillaume P; Luescher I; Old LJ; Shiku H; Nishikawa H
    J Immunol; 2010 Sep; 185(6):3768-76. PubMed ID: 20733202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
    Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
    Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide vaccines in breast cancer: The immunological basis for clinical response.
    Peres Lde P; da Luz FA; Pultz Bdos A; Brígido PC; de Araújo RA; Goulart LR; Silva MJ
    Biotechnol Adv; 2015 Dec; 33(8):1868-77. PubMed ID: 26523780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response.
    Dziadek S; Hobel A; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2005 Nov; 44(46):7630-5. PubMed ID: 16247815
    [No Abstract]   [Full Text] [Related]  

  • 18. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
    Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
    Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines.
    Varypataki EM; Benne N; Bouwstra J; Jiskoot W; Ossendorp F
    Cancer Immunol Res; 2017 Mar; 5(3):222-233. PubMed ID: 28143806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for cancer: synthetic carbohydrate-based vaccines.
    Buskas T; Thompson P; Boons GJ
    Chem Commun (Camb); 2009 Sep; (36):5335-49. PubMed ID: 19724783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.